cbdMD (YCBD) Cash & Equivalents (2016 - 2026)

cbdMD has reported Cash & Equivalents for 10 years, with the latest figure at $3.4 million in Q4 2025.

• Quarterly Cash & Equivalents rose 71.96% year-over-year to $3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.4 million (up 71.96% YoY) and the FY2025 annual result came in at $2.3 million, down 7.8% from the prior year.
• Cash & Equivalents grew to $3.4 million in Q4 2025 per YCBD's latest filing, from $2.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $26.4 million in Q3 2021 and troughed at $1.1 million in Q2 2025.
• A 5-year average of $7.4 million and a median of $2.6 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2023: Cash & Equivalents surged 78.16% in 2021, then tumbled 87.11% in 2023.
• Over 5 years, Cash & Equivalents stood at $19.7 million in 2021, then slumped by 82.98% to $3.4 million in 2022, then plunged by 55.11% to $1.5 million in 2023, then soared by 30.92% to $2.0 million in 2024, then soared by 71.96% to $3.4 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.4 million, $2.3 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.